echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > WuXi AppTec was named "2022 ESG Industry's Highest Rated Company" by Sustainalytics

    WuXi AppTec was named "2022 ESG Industry's Highest Rated Company" by Sustainalytics

    • Last Update: 2022-05-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>
    /* Style Definitions */ span.
    prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
    prnews_a { color:blue; } li.
    prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
    prnews_p { font-size:0.
    62em; font-family:"Arial"; color:black; margin:0in; }

    SHANGHAI, April 8, 2022 /PRNewswire/ -- Recently, WuXi AppTec was awarded the "2022 ESG (Environmental, Social and Governance) Industry's Highest Rating Enterprise" by Sustainalytics, a well-known international rating agency
    .
    According to the report, WuXi AppTec's ESG rating is "low risk", ranking in the top 4% of the global pharmaceutical industry

    .
    This achievement fully reflects that WuXi AppTec has integrated ESG concepts into all aspects of the company's strategy and operations, and has fully implemented the company's commitments in the field of environmental, social and governance

    .


    In 2021, WuXi PharmaTech has consolidated its ESG management system, continuously identifying and integrating hundreds of ESG-related measures in its global business, in business ethics, emissions, wastewater and waste management, occupational health and safety, human capital and corporate governance.
    Significant progress has been made in governance and other areas, and these results have been highly recognized by Sustainalytics

    .

    "Thank you to Sustainalytics for evaluating WuXi AppTec's ESG work results," said Mr.
    Hu Zhengguo, WuXi AppTec's Vice Chairman and Chairman of the ESG Committee

    .
    "We will continue to adhere to the operating philosophy of sustainable development, actively fulfill our corporate social responsibility, and help our partners to accelerate the advent of new drugs and breakthrough therapies for the benefit of patients around the world

    .
    "

    Sustainalytics is a leading provider of ESG research, ratings and data to develop and implement responsible investment strategies for global investors
    .
    Sustainalytics' ESG risk rating covers more than 14,000 companies around the world, comprehensively assesses the major ESG risks faced by companies in specific industries, and analyzes companies' risk management capabilities

    .

    About WuXi AppTec

    WuXi AppTec (stock code: 603259.
    SH/2359.
    HK) provides integrated, end-to-end new drug R&D and production services for the global biopharmaceutical industry, with operating bases in Asia, Europe, and North America

    .
    Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers the R&D threshold, helps customers improve R&D efficiency, and brings more breakthrough treatment solutions to patients.
    The service scope covers chemical drug R&D and production, biological Research, preclinical testing and clinical trial development, cell and gene therapy development, testing and production

    .
    In 2021, WuXi AppTec will be rated AA for ESG (Environmental, Social and Governance) by MSCI

    .
    At present, the company's empowerment platform is carrying the R&D and innovation projects of more than 5,700 partners from more than 30 countries around the world.
    medicine, incurable disease" vision

    .
    For more information, please visit the company website:

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.